These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 14744786

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
    Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC.
    Blood; 2003 Oct 01; 102(7):2615-22. PubMed ID: 12816865
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
    Cuneo KC, Fu A, Osusky K, Huamani J, Hallahan DE, Geng L.
    Anticancer Drugs; 2007 Aug 01; 18(7):793-800. PubMed ID: 17581301
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
    Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M.
    World J Gastroenterol; 2008 Jun 21; 14(23):3681-92. PubMed ID: 18595135
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
    Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M.
    World J Gastroenterol; 2007 Sep 21; 13(35):4761-70. PubMed ID: 17729398
    [Abstract] [Full Text] [Related]

  • 11. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
    Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K.
    Mol Cancer Ther; 2003 Oct 21; 2(10):971-84. PubMed ID: 14578462
    [Abstract] [Full Text] [Related]

  • 12. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K.
    Cancer Res; 2004 Apr 01; 64(7):2580-9. PubMed ID: 15059915
    [Abstract] [Full Text] [Related]

  • 13. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC.
    Clin Cancer Res; 2005 May 01; 11(9):3392-401. PubMed ID: 15867240
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
    Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O.
    Proc Natl Acad Sci U S A; 1999 Apr 13; 96(8):4592-7. PubMed ID: 10200307
    [Abstract] [Full Text] [Related]

  • 16. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
    Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S, Hoelzer D, Atadja P, Ruthardt M, Ottmann OG.
    Haematologica; 2004 Apr 13; 89(4):419-26. PubMed ID: 15075075
    [Abstract] [Full Text] [Related]

  • 17. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 18. The discovery of NVP-LAQ824: from concept to clinic.
    Remiszewski SW.
    Curr Med Chem; 2003 Nov 15; 10(22):2393-402. PubMed ID: 14529481
    [Abstract] [Full Text] [Related]

  • 19. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
    Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K.
    Clin Cancer Res; 2004 Aug 01; 10(15):4991-7. PubMed ID: 15297399
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.